Core Viewpoint - Bank of America maintains a "Buy" rating on MicroPort Medical, citing attractive risk-reward dynamics and a diversified high-value consumables product portfolio [1] Group 1: Business Growth Potential - The surgical robotics segment is expected to be a key growth driver, projected to contribute 19% of total revenue by 2034 [1] - The company is addressing liquidity concerns and aims to achieve profitability by the first half of 2026 through cost control and divesting non-core assets [1] Group 2: Financial Support and Governance - Shareholder Shanghai Industrial Group is anticipated to provide financial and operational support, as well as improvements in the company's governance structure [1] Group 3: Revenue Forecast and Target Price - Total revenue forecasts for 2026 to 2034 have been adjusted upward by 0.1% to 1.5%, with the target price slightly increased from HKD 16.8 to HKD 17 [1]
大行评级丨美银：微升微创医疗目标价至17港元 重申“买入”评级